Compare ISD & PACB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | ISD | PACB |
|---|---|---|
| Founded | 2012 | 2000 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Trusts Except Educational Religious and Charitable | Biotechnology: Laboratory Analytical Instruments |
| Sector | Finance | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 488.5M | 459.0M |
| IPO Year | N/A | 2010 |
| Metric | ISD | PACB |
|---|---|---|
| Price | $13.37 | $1.41 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $2.10 |
| AVG Volume (30 Days) | 94.6K | ★ 5.2M |
| Earning Date | 01-01-0001 | 05-04-2026 |
| Dividend Yield | ★ 9.69% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $93,468,000.00 |
| Revenue This Year | N/A | $11.22 |
| Revenue Next Year | N/A | $12.41 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 3.04 |
| 52 Week Low | $11.82 | $0.85 |
| 52 Week High | $14.79 | $2.73 |
| Indicator | ISD | PACB |
|---|---|---|
| Relative Strength Index (RSI) | 22.75 | 38.63 |
| Support Level | N/A | $1.36 |
| Resistance Level | $14.67 | $1.51 |
| Average True Range (ATR) | 0.19 | 0.09 |
| MACD | -0.12 | 0.00 |
| Stochastic Oscillator | 12.33 | 26.47 |
PGIM High Yield Fund Inc is a diversified, closed-end management investment company, active in the financial services domain. The fund's primary investment objective is to provide a high level of current income, with its secondary objective being capital appreciation. It invests at least eighty percent of its investable assets in a diversified portfolio of high-yield fixed-income instruments that are rated below investment grade with varying maturities and other investments.
Pacific Biosciences of California Inc is a biotechnology company focused on designing, developing, and manufacturing sequencing solutions that enable scientists and clinical researchers to improve their understanding of the genome and ultimately, resolve genetically complex problems. It operates in, one reportable segment: the development, manufacturing, and marketing of an integrated platform for genetic analysis. The majority of the company's revenue is derived from Americas, followed by Europe Middle East, and Africa and Asia-Pacific.